title: Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
abstract: OBJECTIVE
  To evaluate the response rate and progression free and overall survival of patients with advanced endometrial cancer treated with paclitaxel, carboplatin and amifostine. To evaluate the toxicity of amifostine when used in combination with carboplatin and paclitaxel.
  
  
  METHODS
  Forty-seven eligible patients (median age: 66; range 45-82) with bidimensionally measurable advanced, recurrent, or refractory endometrial cancer were treated with carboplatin (AUC = 6), paclitaxel (175 mg/M2) and amifostine (740 mg/M2) every 4 weeks for 6 cycles or until disease progression or unacceptable toxicity.
  
  
  RESULTS
  There were 4 CRs (8%) (2 confirmed, 2 unconfirmed) and 15 PRs (32%) (9 confirmed, 6 unconfirmed) for a total response rate of 40% (95% confidence interval [CI], 26% to 56%). The median progression-free survival (PFS) was 7 months (95% CI, 6-9 months) and a 6-month PFS rate of 64% (95% CI, 50% to 78%). The median overall survival was 14 months (95% CI, 12 to 17 months). Toxicity was tolerable. While 79% of patients developed Grade 3/4 neutropenia (30% Grade 3, 49% Grade 4), there were no episodes of Grade 4 febrile neutropenia and one episode of infection with grades 3-4 neutropenia.
  
  
  CONCLUSIONS
  The combination of paclitaxel and carboplatin with amifostine was well reasonably tolerated in this cohort. The regimen demonstrated significant activity in endometrial cancer, comparable to other multi-agent chemotherapy programs in terms of response rate and survival, and with a favorable toxicity profile.
authors.affiliation: University of California Davis Medical Center, Sacramento, CA 95817, USA.
authors.forename: Sidney A
authors.initials: SA
authors.lastname: Scudder
authors.forename: P Y
authors.initials: PY
authors.lastname: Liu
authors.forename: Sharon P
authors.initials: SP
authors.lastname: Wilczynski
authors.forename: Harriet O
authors.initials: HO
authors.lastname: Smith
authors.forename: Caroline
authors.initials: C
authors.lastname: Jiang
authors.forename: Alton V
authors.initials: AV
authors.lastname: Hallum
authors.forename: Gregory B
authors.initials: GB
authors.lastname: Smith
authors.forename: Edward V
authors.initials: EV
authors.lastname: Hannigan
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
authors.forename: David S
authors.initials: DS
authors.lastname: Alberts
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000369:Aged, 80 and over; D004999:Amifostine / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D016190:Carboplatin; D004999:Amifostine; D017239:Paclitaxel